Available Pharmacological Options and Symptomatic Treatments of Multiple Sclerosis

Abstract

Firas Hasan Bazzari*

Multiple sclerosis is an autoimmune disease that targets the central nervous system and exposes the patients to a higher risk of various disabilities that impair their normal daily life activities. Different approaches take a part in the management of multiple sclerosis, in which pharmacological drug therapy is the corner stone and the central player in the treatment of multiple sclerosis. The pharmacological therapy can be categorized into; disease modifying therapies, symptomatic treatments, and relapse management. The discussed disease modifying therapies include; alemtuzumab, dimethyl fumarate, fingolimod, glatiramer acetate, natalizumab, teriflunomide and beta Interferon-1B, that have been found to share a characteristic feature of altering the immune system baseline functions in order to limit multiple sclerosis complications and deaccelerate its progression. The frequently occurring symptoms of multiple sclerosis are; depression, fatigue, general pain, spasticity, muscle spasm and other symptoms, that need to be care-fully managed. Patients with multiple sclerosis face “on and off” episodes of aggravated symptoms known as a relapse that may last for days, weeks or even months. The National Institute for Health and Care Excellence guidelines have recommended the use of high corticosteroid doses as the gold-standard practice in managing a relapse episode. This review article will provide an overview of the different pharmacological therapies and their major role in the management of multiple sclerosis; via exploring the most recent published scientific evidence. In the end, a general discussion is added, focusing on the role of pharmacists and other medical experts in the clinical management of multiple sclerosis and patient support.

 

How to Cite this Article
Pubmed Style

Firas Hasan Bazzari. Available Pharmacological Options and Symptomatic Treatments of Multiple Sclerosis. SRP. 2018; 9(1): 17-21. 
doi:10.5530/srp.2018.1.4

Web Style

Firas Hasan Bazzari. Available Pharmacological Options and Symptomatic Treatments of Multiple Sclerosis. http://www.sysrevpharm.org/?mno=302644542 [Access: March 28, 2021]. doi:10.5530/srp.2018.1.4

AMA (American Medical Association) Style

Firas Hasan Bazzari. Available Pharmacological Options and Symptomatic Treatments of Multiple Sclerosis. SRP. 2018; 9(1): 17-21. doi:10.5530/srp.2018.1.4



Vancouver/ICMJE Style

Firas Hasan Bazzari. Available Pharmacological Options and Symptomatic Treatments of Multiple Sclerosis. SRP. (2018), [cited March 28, 2021]; 9(1): 17-21. doi:10.5530/srp.2018.1.4



Harvard Style

Firas Hasan Bazzari (2018) Available Pharmacological Options and Symptomatic Treatments of Multiple Sclerosis. SRP, 9 (1), 17-21. doi:10.5530/srp.2018.1.4



Turabian Style

Firas Hasan Bazzari. 2018. Available Pharmacological Options and Symptomatic Treatments of Multiple Sclerosis. Systematic Reviews in Pharmacy, 9 (1), 17-21. doi:10.5530/srp.2018.1.4



Chicago Style

Firas Hasan Bazzari. "Available Pharmacological Options and Symptomatic Treatments of Multiple Sclerosis." Systematic Reviews in Pharmacy 9 (2018), 17-21. doi:10.5530/srp.2018.1.4



MLA (The Modern Language Association) Style

Firas Hasan Bazzari. "Available Pharmacological Options and Symptomatic Treatments of Multiple Sclerosis." Systematic Reviews in Pharmacy 9.1 (2018), 17-21. Print. doi:10.5530/srp.2018.1.4



APA (American Psychological Association) Style

Firas Hasan Bazzari (2018) Available Pharmacological Options and Symptomatic Treatments of Multiple Sclerosis. Systematic Reviews in Pharmacy, 9 (1), 17-21. doi:10.5530/srp.2018.1.4


Most Viewed Articles
  • Dental Development between Assisted Reproductive Therapy (Art) and Natural Conceived Children: A Comparative Pilot Study Norzaiti Mohd Kenali, Naimah Hasanah Mohd Fathil, Norbasyirah Bohari, Ahmad Faisal Ismail, Roszaman Ramli SRP. 2020; 11(1): 01-06 » doi: 10.5530/srp.2020.1.01
  • Psychometric properties of the World Health Organization Quality of life instrument, short form: Validity in the Vietnamese healthcare context Trung Quang Vo*, Bao Tran Thuy Tran, Ngan Thuy Nguyen, Tram ThiHuyen Nguyen, Thuy Phan Chung Tran SRP. 2020; 11(1): 14-22 » doi: 10.5530/srp.2019.1.3
  • A Review of Pharmacoeconomics: the key to “Healthcare for All” Hasamnis AA, Patil SS, Shaik Imam, Narendiran K SRP. 2019; 10(1): s40-s42 » doi: 10.5530/srp.2019.1s.21
  • Deuterium Depleted Water as an Adjuvant in Treatment of Cancer Anton Syroeshkin, Olga Levitskaya, Elena Uspenskaya, Tatiana Pleteneva, Daria Romaykina, Daria Ermakova SRP. 2019; 10(1): 112-117 » doi: 10.5530/srp.2019.1.19
Most Downloaded
  • Dental Development between Assisted Reproductive Therapy (Art) and Natural Conceived Children: A Comparative Pilot Study Norzaiti Mohd Kenali, Naimah Hasanah Mohd Fathil, Norbasyirah Bohari, Ahmad Faisal Ismail, Roszaman Ramli SRP. 2020; 11(1): 01-06 » doi: 10.5530/srp.2020.1.01
  • Manilkara zapota (L.) Royen Fruit Peel: A Phytochemical and Pharmacological Review Karle Pravin P, Dhawale Shashikant C SRP. 2019; 10(1): 11-14 » doi: 0.5530/srp.2019.1.2
  • Pharmacognostic and Phytopharmacological Overview on Bombax ceiba Pankaj Haribhau Chaudhary, Mukund Ganeshrao Tawar SRP. 2019; 10(1): 20-25 » doi: 10.5530/srp.2019.1.4
  • A Review of Pharmacoeconomics: the key to “Healthcare for All” Hasamnis AA, Patil SS, Shaik Imam, Narendiran K SRP. 2019; 10(1): s40-s42 » doi: 10.5530/srp.2019.1s.21
  • A Prospective Review on Phyto-Pharmacological Aspects of Andrographis paniculata Govindraj Akilandeswari, Arumugam Vijaya Anand, Palanisamy Sampathkumar, Puthamohan Vinayaga Moorthi, Basavaraju Preethi SRP. 2019; 10(1): 15-19 » doi: 10.5530/srp.2019.1.3